Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.

Hepatocellular Carcinoma With Portal Vein Thrombosis Clinical Trial

Official title: A Prospective Randomized Controlled Trial Comparing Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis

Status Withdrawn

Clinical Trial Summary

Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic variceal ligation. They will be followed to assess the rate of reduction of index bleed rate as well as survival difference between the groups.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma With Portal Vein Thrombosis
• Thrombosis
• Venous Thrombosis

• NCT number: NCT01659346
• Study type: Interventional
• Source: Institute of Liver and Biliary Sciences, India
• Status: Withdrawn
• Phase: N/A
• Start date: February 2016
• Completion date: December 2017